Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 2,496 Shares of Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Henry Pelish sold 2,496 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $242,910.72. Following the completion of the transaction, the insider directly owned 68,552 shares in the company, valued at approximately $6,671,480.64. This represents a 3.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Nuvalent Stock Performance

Nuvalent stock traded up $9.62 during trading on Wednesday, reaching $106.82. 895,694 shares of the company’s stock were exchanged, compared to its average volume of 779,373. Nuvalent, Inc. has a 52-week low of $55.53 and a 52-week high of $112.88. The firm has a market cap of $7.77 billion, a price-to-earnings ratio of -20.08 and a beta of 1.32. The company’s 50-day moving average is $102.57 and its two-hundred day moving average is $88.78.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter in the prior year, the firm earned ($1.28) earnings per share. Analysts anticipate that Nuvalent, Inc. will post -3.86 EPS for the current year.

Key Headlines Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

Analyst Upgrades and Downgrades

NUVL has been the subject of several recent research reports. Stifel Nicolaus increased their price objective on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a research note on Wednesday, October 8th. UBS Group reaffirmed a “buy” rating on shares of Nuvalent in a research note on Wednesday, December 17th. Leerink Partners boosted their price objective on shares of Nuvalent from $140.00 to $149.00 and gave the stock an “outperform” rating in a report on Monday, November 17th. Finally, HC Wainwright upped their price objective on shares of Nuvalent from $130.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Fifteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $138.33.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC grew its holdings in Nuvalent by 6.6% during the 1st quarter. Voya Investment Management LLC now owns 120,311 shares of the company’s stock worth $8,532,000 after acquiring an additional 7,414 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Nuvalent by 24.5% in the 2nd quarter. Rhumbline Advisers now owns 66,029 shares of the company’s stock valued at $5,038,000 after purchasing an additional 13,003 shares in the last quarter. Voleon Capital Management LP bought a new position in shares of Nuvalent during the first quarter worth about $1,489,000. Norges Bank acquired a new position in Nuvalent in the second quarter worth about $28,582,000. Finally, Strs Ohio acquired a new position in Nuvalent in the first quarter worth about $404,000. 97.26% of the stock is currently owned by institutional investors.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.